CorMedix CRMD Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Merck & Co.MRK

——

Mirum Pharmaceuticals, Inc.MIRM

——

Rigel PharmaceuticalsRIGL

——

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?: CorMedix (CRMD) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $0 in Q4 2025.
What is the long-term trend for CorMedix's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?: Over 2 years (2022 to 2025), CorMedix's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -100.0% compound annual growth rate (CAGR), from $4.14K to $0.